Description
Skyrizi (risankizumab) is a monoclonal antibody targeting IL-23 for the treatment of plaque psoriasis.
$3,742.32
IL-23 inhibitor for psoriasis
Skyrizi (risankizumab) is a monoclonal antibody targeting IL-23 for the treatment of plaque psoriasis.
Reviews
There are no reviews yet.